Shared Decision Making for Patients With First-admission Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01869660|
Recruitment Status : Completed
First Posted : June 5, 2013
Last Update Posted : December 30, 2015
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Behavioral: Shared Decision Making||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Shared Decision Making for Patients With First-admission Schizophrenia: a Randomized Controlled Trial|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||October 2015|
Experimental: Shared Decision Making
The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
Behavioral: Shared Decision Making
The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
No Intervention: Usual Care
Patients with no special program about decision making.
- Patient satisfaction as measured by the Japanese version of the Client Satisfaction Questionnaire (CSQ-8) [ Time Frame: Within 7days before the date of discharge ]
- Attitude toward medication as measured by the Japanese version of the Drug Attitude Inventory (DAI-10) [ Time Frame: Within 7days before the date of discharge ]
- Treatment continuation as measured by the rate of outpatient attendance during the 30 days [ Time Frame: 6 months after discharge ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01869660
|Numazu Chuou Hospital|
|Numazu, Shizuoka, Japan|
|Study Chair:||Yoshio Hirayasu, PhD||Department of Psychiatry, Yokohama City University School of Medical|